Psychiatry

Drew H. Barzman, MD

Title

Assistant Professor - Division of Child and Adolescent Psychiatry

Appointment

Assistant Professor

Email

drew.barzman@cchmc.org

Phone

513-636-8727

Fax

513-636-4788

Credentials

MD: Buffalo, School of Medicine, State University of New York, 1997.

Residency: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 1997-2001.

Fellowship: Forensic Fellow, Department of Psychiatry, University of Cincinnati, Cincinnati, OH, 2001-2002.

Fellowship: Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, 2002-2004.

Licensure: State of Ohio Medical License, 2001.

Certifications:

Diplomat of the American Board of Psychiatry and Neurology, 2002.
Forensic Psychiatry Subspecialty, 2003.
Child and Adolescent Psychiatry Subspecialty, 2004.

Position History

Assistant Professor of Psychiatry and Pediatrics, Cincinnati Children's Hospital Medical Center, July 2004 - present.

Assistant Professor of Psychiatry, University of Cincinnati, July 2004 - present.

Director, Child and Adolescent Forensic Psychiatry Service, Cincinnati Children's Hospital Medical Center, June 2006 - present.

Founder and Moderator, Child and Adolescent Forensic Forum, Cincinnati Children's Hospital Medical Center, 2002 - 2004.

Child and Adolescent Fellow (Psychiatry), University of Cincinnati, 2002 - 2004.

Forensic Fellow (Psychiatry), University of Cincinnati, 2001 - 2002.

Psychiatric Attending Moonlighter, Psychiatric Emergency Room, University of Cincinnati, 2001 - 2004.

Psychiatric Resident Moonlighter, John Umstead Hospital, Butner, NC, 1998 - 2001.

Psychiatry Residency, Duke University Medical Center, Durham, NC, 1997 - 2001.

Research in Neuroimaging, Duke University Medical Center, 1997.

Psychiatry Research Fellowship, State University of New York at Buffalo, School of Medicine, 1994.

Awards and Honors

American Academy of Child and Adolescent Psychiatry Pfizer Travel Grant, 2002
American Academy of Child and Adolescent Psychiatry Presidential Scholar Award, 2004
The University of Cincinnati Biology Psychiatry Resident Research Award, 2004

Research

Child and adolescent forensic psychiatry
Prevention of violence in youth
Neuroimaging in children and adolescents
Genetics
pediatric clinical trials

Research Grants and Contracts

Grant, Principal Investigator:

The Safety and Efficacy of Quetiapine for the Treatment of Aggression in Adolescents with Co-occurring Bipolar Disorder and Disruptive Behavior Disorders.

The Effectiveness and Tolerability of Intramuscular Ziprasidone, 10 mg and 20 mg in the Short-Term Treatment of Acute Agitation from Psychiatric Disorders in Hospitalized Adolescents: A Retrospective Chart Review.

The Aggression Assessment, funded by the Patient Care Innovations Fund, 2006-2007.

A Family-Linked Pilot Study: A Genome Wide Screen for Main Gene Effects for an Endophenotype Linked to Early Onset Conduct Disorder and Alcoholism in Adulthood, Trustee Award, 2006-2008.

Grant, Co-investigator:

Pediatric Bipolar Collaborative Mood Stabilizer Trial (1 RO1 MH63632-01.)

D1441C00149: A 3-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb, Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg and 600 mg Compared with Placebo in the Treatment of Children and Adolescents with Bipolar I Mania.

D1441C00150: A 26-week, International, Multicenter, open-Label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia.

FID-MC-HIGN; Olanzapine vs. Placebo in the Treatment of Adolescents with Schizophrenia.

FID-MC-HGiU; Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar Disorder.

A 27-Week Open-Label Trial to Characterize the Safety and Tolerability of Orally Administered Ziprasidone in Children and Adolescent Subjects with Bipolar Disorder (Manic or Mixed), Schizophrenia or Schizoaffective Disorder.

RIS-BIM-301: Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder.

Protocol RIS –USA-234: The Efficacy and Safety of Risperidone in the Treatment of Adolescents with Schizophrenia: A Follow Up Trial of RIS-USA-231.

Protocol RIS_USA-231: The Efficacy and Safety of Risperidone in the Treatment of Adolescents with Schizophrenia.

D1441C00112: A 6-week, International, Multi-Center., Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel) Immediate-release Tablets in Daily Doses of 400 mg and 800 mg in the Treatment of Children and Adolescents with Schizophrenia.

A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood disorders in Adolescents Who Are at High Risk for Developing Bipolar Disorder.

A Multicenter, Open-Label, Flexible-Dose, Parallel-Group Evaluation of the Caractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long-term Treatment of Patients with Schizophrenia or Schizoaffective Disorder (Clinical Study Protocol 5077IL/0089.)

Publications, Most Recent

Refereed Journals:

Barzman, D.H.; Fieler, L.; Sallee, F.R.: Attention-deficit, hyperactivity disorder diagnosis and treatment: Separating myth from substance.The Journal of Legal Medicine, 2004; 25:23-38.

Barzman, D.H.; Gernert, B.; DelBello, M.P.: Quetiapine for chronic motor tic disorder. The American Journal of Psychiatry, 2004; 161:1307.

Barzman, D.H.; DelBello, M.P.; Kowatch, R.A.; Gernert, B.; Fleck, D.E.; Pathak, S.; Rappaport, K.; Delgado, S.V.; Campbell, P.; Strakowski, S.M.: The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.The Journal of Child and Adolescent Psychopharmacology, 2004; 14:593-600.

Barzman, D.H.; DelBello, M.P.: Clinically useful approaches for the atypical antipsychotics (second generation antipsychotics) in pediatric psychotic disorders.Child and Adolescent Psychopharmacology News, 2004; 9:6-9.

Barzman, D.H.; DelBello, M.P.; Kowatch, R.A.; Warner, J.; Rofey, D.; Rappaport, K.; Daniels, J.P.; Strajowski, S.M.: Adjunctive topiramate in hospitalized pediatric patients with bipolar disorders.The Journal of Child and Adolescent Psychopharmacology, 2005; 15:931-937.

DelBello, M.P.; Kowatch, R.A.; Adler, C.M.; Stanford, K.E.; Welge, J.A.; Barzman, D.H.; Nelson, E.; Strakowski, S.M.: A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2006; 45:305-313.

Barzman, D.H.; McConville, B.J.; Masterson, B.; McElroy, S.; Sethuraman, G.; Moore, K.; Kahwaty, A.M.; Nelson, D.: Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?Journal of Affective Disorders, 2005; 88:279-85.

Barzman, D.H.; DelBello, M.P.: Topiramate for co-occurring bipolar disorder and disruptive behavior disorders.Am J Psychiatry, 2006; 163:1451-2.

Barzman, D.H.; DelBello, M.P.; Adler, C.M.; Stanford, K.E.; Strakowski, S.M.: The Efficacy and Tolerability of Quetiapine versus Divalproex for the Treatment of Impulsivity and Reactive Aggression in Adolescents with Co-occurring Bipolar Disorder and Disruptive Behavior Disorder(s).The Journal of Child and Adolescent Psychopharmacology, in press for December 2006.

Barzman, D.H.; DelBello, M.P.; Fleck, D.E.; Lehmkuhl, H.; Strakowski, S.M.: Rates, types, and psychosocial correlates of legal charges in adolescents with newly diagnosed bipolar disorder.Bipolar Disorders, in press for 2007.

Other Publications:

Barzman, D.H.: Atypical antipsychotic polypharmacy for schizophrenia: show me the evidence. Case Studies, Psychiatry Source, June 2005.

Presentations, Most Recent:

Lee Malvo: Did He Meet Criteria for NGRI and Lionel Tate v. State of Florida: What Should Have Been the Fate for Lionel Tate? Lunch and Learn at Summit Behavioral Healthcare; April 1, 2004.

Aripiprazole for Pediatric Bipolar Disorder: A Retrospective Chart Review. Poster Presentation at the New Research Program at the American Psychiatric Association 2004 Annual Meeting, New York, NY.

Lectures for the Forensic Psychiatry Fellowship at the University of Cincinnati:

Competence to Stand Trial II: Tools for Measuring Competence. August 25, 2004; August 10, 2005; August 16, 2006.
Criminal Responsibility II: Amnesia, Intoxication, TBI. September 8, 2004.
Duty to Warn / Protect. December 1, 2004.
School Violence. January 5, 2005; January 11, 2006.
Juvenile Forensics Overview. March 16, 2005; April 6, 2006.
Elements of Informed Consent. March 16, 2005; March 29, 2006.
Forensic Research. April 13, 2005.
Child Abuse and Child Interviewing. May 25, 2005; January 18, 2006.

Other Drugs. Lecture for the Psychopharmacology Course at Cincinnati's Children's Hospital Medical Center; October 28, 2004.

Lee Malvo: Did He Meet Criteria for NGRI? Forensic Lecture Series for the Child and Adolescent Psychiatry Fellowship at Cincinnati's Children Hospital Medical Center; September 19, 2005.

Lee Malvo: Did he meet Criteria for NGRI? Presented at the M.I.N.D. Institute; Sacramento, CA; August 27, 2004.

The Identification of a Subtype of Adolescents with Bipolar Disorder Who Offend Prior to Treatment for the First Episode of Mania. Poster Presentation at the New Research Poster Session at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Washington, DC; October 2004.

A Double-Blind Comparison of Divalproex versus Quetiapine for Adolescent Mania. Poster Presentation at the New Research Poster Session at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Washington, DC; October 2004.

Comparison of Divalproex and Quetiapine Monotherapy for Adolescent Mania. Poster Presentation at the New Research Poster Session at the 158th Annual Meeting of the American Psychiatric Association; Atlanta, GA; May 2005.

Treatment for Aggression in Bipolar Adolescents with Disruptive Behavior Disorders. Poster Presentation at the New Research Poster Session at the 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Toronto, Canada; October 2005.

The Identification of Risk and Protective Factors for Offending Behaviors in Bipolar Adolescents. Poster Presentation at the Poster Session at the American Academy of Psychiatry and the Law 2005 Annual Meeting; Montreal, Canada; October 2005.

Forrester, J.J.; Barzman, D.H.; DelBello, M.P.; Keck, P.E.; Strakowski, S.M.: Intramuscular Ziprasidone for Acute Agitation in Children and Adolescents: a Retrospective Chart Review. Poster Presentation at the Poster Session at the 2006 American Psychiatric Association Annual Meeting in Toronto, Canada.

Violence Prevention on Adolescent Inpatient Psychiatry Units. Discussion Leader for a Clinical Case Conference at Cincinnati Children's Hospital Medical Center; November 4, 2004.

Mental Health and the Juvenile Justice System: Prevalence of Psychiatric Illness in Detained Youth. Mental Health Symposium; March 10, 2005.

Data Collection Techniques, Measurement Validity, and Measurement Reliability: The Application to the Aggression Assessment and the Overt Aggression Scale-Advance. Lecture for the Research Course at Cincinnati Children's Hospital Medical Center; April 21, 2005.

Conduct Disorder (CD) and Oppositional Defiant Disorder (ODD): Bad Kids or Just Undiagnosed and Untreated. ADHD Co-Morbidity Lecture Series; May 11, 2005.

Lectures for the Forensic Psychiatry Didactics at Cincinnati Children's Hospital Medical Center:

Lee Malvo: Did He Meet Criteria for NGRI? September 19, 2005.
Lionel Tate v. State of Florida: What Should Have Been the Fate for Lionel Tate? and Mock Trial. September 26, 2005.
Malpractice. October 1, 2005.
Assessing the Risk for School Violence: People vs. Patrick Smith with a Mock Trial. October 10, 2005; October 17, 2005.
Child and Adolescent Forensic Landmark Cases. October 24, 2005.
Munchausen by Proxy. October 31, 2005; November 7, 2005.
Pediatric Aggression: Etiology, Diagnosis, and Treatment. November 14, 2005.
Correctional Psychiatry: Mad, Bad, or Just Sad? November 28, 2005.
Custody. December 5, 2005.

Psychiatric Diagnosis and Treatment Related to Pediatric Aggression. Presented at the Summit Behavioral Healthcare Lecture Series; July 28, 2005.

Pediatric Aggression: Beyond Bipolar Disorder. Mental Health Workshop at Children's Home; November 14, 2005.

Pediatric Aggression: The Biological Basis, Diagnosis, and Treatment. Presented at the pediatric resident's noon conference at Cincinnati Children's Hospital Medical Center; December 8, 2005.

Pediatric Aggression: Practical Approaches and Research. Presented at Pediatric Grand Rounds at Cincinnati Children's Hospital Medical Center; February 28, 2006.

Disruptive Behavior Disorders (ODD/CD, Violence, Homicide.) Presented at the American Academy of Child and Adolescent Psychiatry 31st Annual Review Course; March 2, 2006.

Divalproex Treatment for Youth with Explosive Temper and Mood Lability: A Double-Blind, Placebo-Controlled Crossover Design. Journal Club review; March 28, 2006.